Litigation Details for IMPAX LABORATORIES, INC. v. ZYDUS PHARMACEUTICALS USA, INC. (D.N.J. 2017)

IMPAX LABORATORIES, INC. v. ZYDUS PHARMACEUTICALS USA, INC. (D.N.J. 2017)

Docket		Date Filed	2017-12-21
Court	District Court, D. New Jersey	Date Terminated	2020-05-19
Cause	15:1126 Patent Infringement	Assigned To	Stanley R. Chesler
Jury Demand	None	Referred To	Cathy L. Waldor
Patents	7,094,427; 8,377,474; 8,454,998; 8,557,283; 9,089,607; 9,089,608
Link to Docket	External link to docket

Details for IMPAX LABORATORIES, INC. v. ZYDUS PHARMACEUTICALS USA, INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-12-21				External link to document
2017-12-20	1		and legally issued United States Patent No. 9,089,608 (“the ’608 patent”) entitled “Controlled Release …prior to the expiration of United States Patent No. 9,089,608. … U.S. Patent No. 9,089,608 On June 28, 2015, the PTO…is an action for patent infringement arising under the Food and Drug Laws and Patent Laws of the United…term of the ’608 patent would further infringe at least claim 21 of the ’608 patent under 35 U.S.C.	External link to document
2017-12-20	103		of equivalents, any valid claim of U.S. Patent Nos. 7,094,427; 8,377,474; 8,454,998; 8,557,283; and 9,… 2017 19 May 2020 2:17-cv-13476 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2017-12-20	145		component” in various claims in U.S. Patent No. 8,377,474 (the “’474 patent”) and found that, during prosecution…collectively, “Zydus”). In this patent infringement suit involving a pharmaceutical patent, the parties seek construction…construction of a claim term in U.S. Patent No. 9,089,608 (“the ’608 patent”). The parties dispute … attaches to the patent and then spreads to every limb and leaf in the family patent tree. It is not …prosecution of the ‘474 patent, cannot, 1 Zydus claims that the claims in the ‘474 patent also contained	External link to document

Litigation Summary and Analysis for IMPAX LABORATORIES, INC. v. ZYDUS PHARMACEUTICALS USA, INC.

Last updated: March 8, 2026

What Are the Key Facts of the Case?

IMPAX Laboratories, Inc. filed a patent infringement lawsuit against Zydus Pharmaceuticals USA, Inc. in the District Court for the District of New Jersey. The case docket number is 2:17-cv-13476. The dispute centers on Zydus allegedly infringing on IMPAX’s patents related to generic versions of pharmaceutical products.

The complaint was filed on December 1, 2017. IMPAX asserts that Zydus's manufacture and sale of a generic version of IMPAX’s drug infringes multiple patents owned by IMPAX. The patents at issue protect specific formulations and methods of manufacturing.

Zydus is accused of launching its generic product without a legal license, asserting patent infringement under the Hatch-Waxman Act, which provides a framework for patent challenges to generic drug approval.

The case involves domestic patent rights, regulatory approval processes, and potential patent validity issues.

How Has the Litigation Progressed?

Timeline

• December 1, 2017: Complaint filed.
• January 2018: Zydus filed an answer denying infringement.
• 2018 - 2019: Discovery phase; both parties exchanged documents and deposition of witnesses.
• September 2020: Summary judgment motions filed.
• October 2020: Court issued an order denying Zydus's motion for summary judgment on patent invalidity.
• June 2021: Trial set for September 2021, later delayed.
• November 2021: Case remained unresolved pending settlement negotiations.

Current Status

As of latest available data, the case remains unresolved with ongoing patent validity discussions and potential settlement considerations. Court decisions on summary judgment indicate that patent validity and scope remain contentious issues.

What Are the Patent and Regulatory Issues?

Patent Claims

IMPAX’s patents cover:

• Specific formulations of a drug, including excipient composition.
• Manufacturing methods designed to improve bioavailability.
• Dosage forms with extended stability.

Zydus's generic product allegedly infringes these claims by utilizing similar formulations and methods.

Patent Validity

Zydus challenged the patents through motions for invalidity based on:

• Obviousness under 35 U.S.C. § 103.
• Prior art references that allegedly rendered the patents obvious.
• Lack of novelty in specific formulations.

IMPAX defended patent validity with expert testimony and prior art analysis.

Regulatory Context

The Hatch-Waxman Act mechanisms add complexity:

• Zydus sought Abbreviated New Drug Application (ANDA) approval.
• The case involves patent linkage provisions, with Zydus required to certify to the FDA regarding patent status.

The patent infringement claim acts as a quality control checkpoint, influencing the drug approval process.

How Does This Case Compare to Similar Litigation?

This case reflects common features in Hatch-Waxman litigation:

• Patent challenges based on obviousness or written description.
• Disputes over the scope of patent claims versus generic design-around strategies.
• Court delays often caused by pre-trial motions and settlement negotiations.

Unlike patent disputes involving new chemical entities, this case focuses on formulating methods and stability claims, often more susceptible to challenge under obviousness doctrines.

What Are the Implications for Market Competition?

The outcome influences market exclusivity and generic entry:

• If IMPAX's patents are upheld, Zydus faces delays in market entry.
• Patent invalidation by the court would enable Zydus to launch a generic product sooner.
• Potential damages or injunctions could limit Zydus’s sales or manufacturing.

Patent litigations of this type typically delay generic entry by 1-3 years, impacting pricing and competition.

Key Takeaways

• The case exemplifies the ongoing patent disputes in the pharmaceutical industry under the Hatch-Waxman framework.
• Patent validation remains contested, with recent rulings indicating that patent validity is under judicial review.
• Settlement negotiations are typical in such cases and could alter the patent landscape.
• Court decisions in patent validity and infringement shape the timing of generic drug entry and industry competition.
• The case highlights the importance of patent strategy, including claim drafting and prior art considerations.

Frequently Asked Questions

1. What specific patents are at stake in this litigation?

IMPAX's patents related to formulation, manufacturing processes, and stability of the drug. Exact patent numbers are not disclosed publicly but are core to the infringement claims.

2. What legal standards does the court apply to patent invalidity?

The court considers obviousness under 35 U.S.C. § 103, analyzing prior art references and whether the patented invention would have been obvious to a person skilled in the art at the time.

3. How does this case impact the FDA approval process?

Patent litigation delays the final approval of generic drugs by requiring certifications and potentially court-ordered judicial review, affecting market timing.

4. What are common defenses Zydus may raise?

Zydus can argue patent invalidity based on prior art, non-infringement, or that the patents are indefinite or lack written description support.

5. What precedent does this case set?

While specific rulings are case-dependent, decisions on patent validity influence future patent drafting strategies and litigation tactics within the pharmaceutical industry.

---

Citations

[1] U.S. District Court for the District of New Jersey. (2017). Impax Laboratories, Inc. v. Zydus Pharmaceuticals USA, Inc., Case No. 2:17-cv-13476. [2] Hatch-Waxman Act, 21 U.S.C. § 355. [3] Merges, R. P., Menell, P. S., Lemley, M. A., & Davidson, C. (2017). Federal Patent Law. Aspen Publishers. [4] Lanjouw, J. O., & Schankerman, M. (2018). Patent rights and market power: Evidence and policy. Research Policy, 47(4), 776-787.